IJCRR - Vol 06 Issue 13, July, 2014
HYPERTRIGLYCERIDEMIA IN CHRONIC KIDNEY DISEASE - A CLINICALLY RELEVANT STUDY
Author: Sanjay H. Kalbande, Takkallapalli Anitha
Background: Cardiovascular disease is the major cause of mortality and morbidity in patients with chronic kidney disease [CKD] Hypertriglyceridemia may contribute to the progression of atherosclerosis and it is considered to be an independent risk factor for patients of chronic kidney disease. Aim: To study the effects of hypertriglyceridemia, especially in males and females suffering from chronic kidney disease, to comparative evaluation of serum triglyceride levels in patients of chronic kidney disease undergoing hamodialysis and patients on conservative therapy. Methodology: Our study included 100 patients of chronic kidney disease, of which 66 were males and 34 were females. Results: On decade wise grouping, we found maximum number of patients of chronic kidney disease between 51-60 years (42.8%) followed by 61-70 years (40%). The most common cause of chronic kidney disease was found to be type II diabetes mellitus (38%), followed by hypertension (32%) and hypertension 18%. The mean triglyceride levels in both males and females were less than 150 mg/dl in 40% of patients followed by borderline high in 32% and very high in 28% of chronic kidney disease patients. The mean serum triglycerides in patients on conservative therapy was 151.2±35.31 and in patients undergoing haemodialysis, the mean serum triglycerides was 205.8 ± 69.72. Conclusion: Our study shows that patients of chronic kidney disease have elevated serum triglycerides, in patients on Haemodialysis there is hypertriglyceridemia which could contribute to atherosclerosis and cardiovascular disease.
Keywords: Chronic kidney disease [CKD], Maintenance haemodialysis, [MHD] Serum triglycerides.
Sanjay H. Kalbande, Takkallapalli Anitha. HYPERTRIGLYCERIDEMIA IN CHRONIC KIDNEY DISEASE - A CLINICALLY RELEVANT STUDY International Journal of Current Research and Review. Vol 06 Issue 13, July, 64-69
1. Dewardener, H.E, An outline of normal and abnormal function. In: The kidney 4th edition. Churchill Livingstone New York 1986;181- 235
2. Munter P, He J, Astor BC, Folsom AR, Coresh J. Traditional and non-traditional risk factors predict coronary heart disease:results from atherosclerosis risk in communities study J.Am. soc Nephrol.2005;16:529-38
3. Assman G, Schulte H, Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Munster study. Am J cardio. 1992;70:733-737
4. Castelli;wp. The triglyceride issue: a view from fremingh am, Am Heart J 1986:112:432- 7.
5. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J kidney Dis. 1998;32:S142-S156
6. Weiner DE, Tighiouart H. stark PC, Amin MG, Macleod B, Griffith JL et al. kidney disease as a risk factor for recurrent cardiovascular disease and mortality Am J kidney Dis 2004; 44:198-206.
7. Feast TG and smith SR: Incidence of advance CRF and need for end stage renal replacement. BMJ / 1990;301,897-900
8. Wing AJ: Courses on end stage renal failure Oxford textbook of clinical nephrology. Oxford university press:1227-36:1992
9. Marrie M, Bouhanick B, Berrut G: Micro albuminuria. Curr opin nephrol Hypertens 3; 558-563, 1994
10. Hillege HL, Fidler V, Diercks GF, Van Gilst WH, dezeecw D, van veldhuisen DJ, Gans RO, Janssen WH, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation, 2002; 106: 1777-1782
11. Green D, stone NJ, Krumlowsky A. Putative atherogenic factors in patients with chronic renal failure. Prog cardiovascular Dis. 1983; 26: 133-144 [pub Med]
12. Shah B, Nair S, Sirsat RA, Ashavaid TF, Nair KG, Dyslipidemia in patients with chronic renal failure and in renal transplant patients. J. Post grad Med. 1994;40;57-60
13. Anderson AJ : Lipoprotein pattern in chronic renal failure (moyo CLIN proc.1976 oct; 51910); 660-4)
14. Vaziri ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63; 1964-1976, 2003
15. Cress man MD, Heyka RJ, Paganini EP, et al Lipoproterin(a) is an independent risk factor for cardio vascular disease in haemodialysis patients. Circulation 1992; 475-82
16. Longenecker JC, coresh J, Powe NR. Traditional cardiovascular disease risk factor on dialysis patients compared with the general population: The CHOICE study.J Am SOC Nephrol 2002; 13(1); 1918-27
17. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factor in chronic haemodialysis patients with special attention to hyper lipoproteinemias. Atherosclerosis 1983;48: 279-88
18. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. AM J kidney Dis2003;41(4 SUPPL):I-IV,S1-S91.